BACKGROUND: Assessment of the change in tumour burden is an important feature of the
clinical evaluation of cancer therapeutics: both tumour shrinkage (objective response) and …

Anticancer cytotoxic agents go through a process by which their antitumor activity—on the
basis of the amount of tumor shrinkage they could generate—has been investigated. In the …

Purpose Objective tumor response rates observed in phase II trials for metastatic melanoma
have historically not provided a reliable indicator of meaningful survival benefits. To …

PURPOSE Taxol (paclitaxel; Bristol-Myers Squibb, Wallingford, CT) is a new anticancer
agent with activity in a number of human tumors, including epithelial ovarian cancer. In …

Purpose Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene, and loss of
function mutations are common and appear to be important in the pathogenesis of …

Paclitaxel and docetaxel are 2 compounds from the new taxoid class of anti-cancer agents.
Both drugs are very similar in preclinical activity, mechanism of action and spectrum of …

Purpose To determine the clinical activity of OGX-011, an antisense inhibitor of clusterin, in
combination with docetaxel/prednisone in patients with metastatic castration-resistant …

Importance The randomized clinical trial (RCT) in oncology has evolved since its widespread
adoption in the 1970s. In recent years, concerns have emerged regarding the use of …

Background: New targeted, non-cytotoxic anticancer agents, such as small-molecule kinase
inhibitors, pose challenges to the current phase I paradigm of dose selection based on …

Purpose We report a multicenter phase II study of patients with metastatic melanoma (MM),
evaluating the efficacy, toxicity, progression-free survival (PFS), immunogenicity, and …